Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials

Aminah Jatoi, Jacob B. Allred, Vera Jean Suman, Edward T. Creagan, Gary A. Croghan, Thomas Amatruda, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The current study was undertaken to explore whether older age predicts adverse event rates in metastatic melanoma patients participating in cancer clinical trials. Methods: Six phase II studies conducted at our institution for patients with metastatic disease were used in these pooled analyses: 1) ABT-510; 2) bortezomib, paclitaxel, and carboplatin; 3) everolimus; 4) bevacizumab, paclitaxel, carboplatin; 5) carboplatin and nab-paclitaxel; and 6) temozolomide and everolimus. In total, 233 patients, 64 elderly (≥ 70. years) and 169 younger, were analyzed for age-based differences in grade 2 or worse adverse events and other clinical outcomes. Results: Despite the fact that older patients had slightly worse performance scores, no differences in rates of adverse events were observed based on age. Only worse baseline performance score predicted a higher rate of adverse events: patients with performance scores of one or worse were almost 4 times more likely to experience adverse events. Median cancer progression free survival and overall survival were comparable between older and younger patients. Conclusion: These findings suggest that concern for adverse event rates should not preclude the enrollment of elderly melanoma patients to cancer clinical trials. Such patients should continue to be monitored carefully for tumor response and toxicity.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalJournal of Geriatric Oncology
Volume3
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Melanoma
Carboplatin
temozolomide
Therapeutics
Paclitaxel
Neoplasms
Clinical Trials
Disease-Free Survival
Survival

Keywords

  • Adverse events
  • Elderly
  • Melanoma
  • Pooled analysis
  • Toxicity

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Oncology

Cite this

Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials. / Jatoi, Aminah; Allred, Jacob B.; Suman, Vera Jean; Creagan, Edward T.; Croghan, Gary A.; Amatruda, Thomas; Markovic, Svetomir Nenad.

In: Journal of Geriatric Oncology, Vol. 3, No. 4, 10.2012, p. 307-311.

Research output: Contribution to journalArticle

@article{b41ef94b7cc84a938334d5f498018a28,
title = "Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials",
abstract = "Background: The current study was undertaken to explore whether older age predicts adverse event rates in metastatic melanoma patients participating in cancer clinical trials. Methods: Six phase II studies conducted at our institution for patients with metastatic disease were used in these pooled analyses: 1) ABT-510; 2) bortezomib, paclitaxel, and carboplatin; 3) everolimus; 4) bevacizumab, paclitaxel, carboplatin; 5) carboplatin and nab-paclitaxel; and 6) temozolomide and everolimus. In total, 233 patients, 64 elderly (≥ 70. years) and 169 younger, were analyzed for age-based differences in grade 2 or worse adverse events and other clinical outcomes. Results: Despite the fact that older patients had slightly worse performance scores, no differences in rates of adverse events were observed based on age. Only worse baseline performance score predicted a higher rate of adverse events: patients with performance scores of one or worse were almost 4 times more likely to experience adverse events. Median cancer progression free survival and overall survival were comparable between older and younger patients. Conclusion: These findings suggest that concern for adverse event rates should not preclude the enrollment of elderly melanoma patients to cancer clinical trials. Such patients should continue to be monitored carefully for tumor response and toxicity.",
keywords = "Adverse events, Elderly, Melanoma, Pooled analysis, Toxicity",
author = "Aminah Jatoi and Allred, {Jacob B.} and Suman, {Vera Jean} and Creagan, {Edward T.} and Croghan, {Gary A.} and Thomas Amatruda and Markovic, {Svetomir Nenad}",
year = "2012",
month = "10",
doi = "10.1016/j.jgo.2012.04.002",
language = "English (US)",
volume = "3",
pages = "307--311",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials

AU - Jatoi, Aminah

AU - Allred, Jacob B.

AU - Suman, Vera Jean

AU - Creagan, Edward T.

AU - Croghan, Gary A.

AU - Amatruda, Thomas

AU - Markovic, Svetomir Nenad

PY - 2012/10

Y1 - 2012/10

N2 - Background: The current study was undertaken to explore whether older age predicts adverse event rates in metastatic melanoma patients participating in cancer clinical trials. Methods: Six phase II studies conducted at our institution for patients with metastatic disease were used in these pooled analyses: 1) ABT-510; 2) bortezomib, paclitaxel, and carboplatin; 3) everolimus; 4) bevacizumab, paclitaxel, carboplatin; 5) carboplatin and nab-paclitaxel; and 6) temozolomide and everolimus. In total, 233 patients, 64 elderly (≥ 70. years) and 169 younger, were analyzed for age-based differences in grade 2 or worse adverse events and other clinical outcomes. Results: Despite the fact that older patients had slightly worse performance scores, no differences in rates of adverse events were observed based on age. Only worse baseline performance score predicted a higher rate of adverse events: patients with performance scores of one or worse were almost 4 times more likely to experience adverse events. Median cancer progression free survival and overall survival were comparable between older and younger patients. Conclusion: These findings suggest that concern for adverse event rates should not preclude the enrollment of elderly melanoma patients to cancer clinical trials. Such patients should continue to be monitored carefully for tumor response and toxicity.

AB - Background: The current study was undertaken to explore whether older age predicts adverse event rates in metastatic melanoma patients participating in cancer clinical trials. Methods: Six phase II studies conducted at our institution for patients with metastatic disease were used in these pooled analyses: 1) ABT-510; 2) bortezomib, paclitaxel, and carboplatin; 3) everolimus; 4) bevacizumab, paclitaxel, carboplatin; 5) carboplatin and nab-paclitaxel; and 6) temozolomide and everolimus. In total, 233 patients, 64 elderly (≥ 70. years) and 169 younger, were analyzed for age-based differences in grade 2 or worse adverse events and other clinical outcomes. Results: Despite the fact that older patients had slightly worse performance scores, no differences in rates of adverse events were observed based on age. Only worse baseline performance score predicted a higher rate of adverse events: patients with performance scores of one or worse were almost 4 times more likely to experience adverse events. Median cancer progression free survival and overall survival were comparable between older and younger patients. Conclusion: These findings suggest that concern for adverse event rates should not preclude the enrollment of elderly melanoma patients to cancer clinical trials. Such patients should continue to be monitored carefully for tumor response and toxicity.

KW - Adverse events

KW - Elderly

KW - Melanoma

KW - Pooled analysis

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84866391602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866391602&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2012.04.002

DO - 10.1016/j.jgo.2012.04.002

M3 - Article

AN - SCOPUS:84866391602

VL - 3

SP - 307

EP - 311

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

IS - 4

ER -